Martin Gleave, MD, FRCSC, FACS, explains how the adaptive, biomarker-driven GUNS trial uses neoadjuvant therapy to link genomic subtypes with treatment response.
Martin Gleave, MD, FRCSC, FACS
Advertisement
Articles by Martin Gleave, MD, FRCSC, FACS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to VIR-5500 for mCRPC
2
FDA grants 510(k) clearance to OpenFlo urinary catheter
3
How can urologists separate personalized medicine from marketing?
4
Why ctDNA serves as a rule-out in NeoBLAST's response assessment
5